Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

734 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation.
Schilbach K, Alkhaled M, Welker C, Eckert F, Blank G, Ziegler H, Sterk M, Müller F, Sonntag K, Wieder T, Braumüller H, Schmitt J, Eyrich M, Schleicher S, Seitz C, Erbacher A, Pichler BJ, Müller H, Tighe R, Lim A, Gillies SD, Strittmatter W, Röcken M, Handgretinger R. Schilbach K, et al. Among authors: seitz c. Oncoimmunology. 2015 Mar 19;4(7):e1014760. doi: 10.1080/2162402X.2015.1014760. eCollection 2015 Jul. Oncoimmunology. 2015. PMID: 26140238 Free PMC article.
Preemptive administration of human αβ T cell receptor-targeting monoclonal antibody GZ-αβTCR potently abrogates aggressive graft-versus-host disease in vivo.
Blank G, Welker C, Sipos B, Sonntag K, Müller F, Eckert F, Seitz C, Nadalin S, LaCorcia G, Königsrainer A, Snell D, Handgretinger R, Schilbach K. Blank G, et al. Among authors: seitz c. Ann Hematol. 2015 Nov;94(11):1907-19. doi: 10.1007/s00277-015-2471-3. Epub 2015 Aug 13. Ann Hematol. 2015. PMID: 26264693
GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells.
Seitz CM, Schroeder S, Knopf P, Krahl AC, Hau J, Schleicher S, Martella M, Quintanilla-Martinez L, Kneilling M, Pichler B, Lang P, Atar D, Schilbach K, Handgretinger R, Schlegel P. Seitz CM, et al. Oncoimmunology. 2019 Nov 7;9(1):1683345. doi: 10.1080/2162402X.2019.1683345. eCollection 2020. Oncoimmunology. 2019. PMID: 32002293 Free PMC article.
Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting.
Seitz CM, Mittelstaet J, Atar D, Hau J, Reiter S, Illi C, Kieble V, Engert F, Drees B, Bender G, Krahl AC, Knopf P, Schroeder S, Paulsen N, Rokhvarguer A, Scheuermann S, Rapp E, Mast AS, Rabsteyn A, Schleicher S, Grote S, Schilbach K, Kneilling M, Pichler B, Lock D, Kotter B, Dapa S, Miltenyi S, Kaiser A, Lang P, Handgretinger R, Schlegel P. Seitz CM, et al. Oncoimmunology. 2021 Dec 2;10(1):2003532. doi: 10.1080/2162402X.2021.2003532. eCollection 2021. Oncoimmunology. 2021. PMID: 35686214 Free PMC article.
First-in-Humans PET/MRI of In Vivo GD2 Expression in Osteosarcoma.
Trautwein NF, Reischl G, Seitz C, Dittmann H, Seith F, Scheuermann S, Feuchtinger T, Dombrowski F, Handgretinger R, Fuchs J, Pichler B, Fougère C, Schwenck J. Trautwein NF, et al. Among authors: seitz c. J Nucl Med. 2023 Feb;64(2):337-338. doi: 10.2967/jnumed.122.264626. Epub 2022 Sep 15. J Nucl Med. 2023. PMID: 36109181 Free PMC article. No abstract available.
A novel approach to guide GD2-targeted therapy in pediatric tumors by PET and [64Cu]Cu-NOTA-ch14.18/CHO.
Trautwein NF, Schwenck J, Seitz C, Seith F, Calderón E, von Beschwitz S, Singer S, Reischl G, Handgretinger R, Schäfer J, Lang P, Pichler BJ, Schulte JH, la Fougère C, Dittmann H. Trautwein NF, et al. Among authors: seitz c. Theranostics. 2024 Jan 20;14(3):1212-1223. doi: 10.7150/thno.92481. eCollection 2024. Theranostics. 2024. PMID: 38323317 Free PMC article.
734 results